Full-Length RNA-Seq Tech Note

Full-Length RNA-Seq: A Novel Method to Assess Sequence Integrity for RNA Therapeutics

The use of RNA therapeutics as a gene therapy is on the rise due to the ability to target specific genes and introduce new transcripts. To develop these therapies, strict quality control is required to ensure the integrity of poly(A) tails, which are critical for translation and stability of mRNA products. However, current assays for measuring poly(A) tails present limitations, such as inaccurate length detection and the introduction of artifacts.

Using NGS-based PacBio® Small-Molecule, Real-Time (SMRT®) sequencing, GENEWIZ from Azenta Life Sciences has developed a high-throughput, full-length RNA sequencing (RNA-Seq) workflow to sequence manufactured products while keeping the full-length poly(A) tail intact. In this tech note, discover the science behind this novel assay and how it’s an optimal approach for quality control for the development of your mRNA-based vaccines or drugs.

What You'll Learn

• Challenges associated with sequencing full-length RNA molecules utilizing traditional approaches
• The full-length RNA-Seq workflow from Azenta to accurately sequence manufactured RNA products
• Results from internal tests to confirm quantification accuracy and consistency of the full-length RNA-Seq assay